Alaunos Therapeutics Stock Today
| TCRT Stock | USD 2.68 0.04 1.47% |
PerformanceWeak
| Odds Of DistressHigh
|
Alaunos Therapeutics is selling for under 2.68 as of the 30th of October 2025; that is 1.47 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 2.63. Alaunos Therapeutics has more than 67 % chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 1st of August 2025 and ending today, the 30th of October 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 24th of August 2005 | Category Healthcare | Classification Health Care |
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. Alaunos Therapeutics, Inc. is headquartered in Houston, Texas. Alaunos Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 2.21 M outstanding shares of which 108.94 K shares are at this time shorted by private and institutional investors with about 0.1 trading days to cover. More on Alaunos Therapeutics
Moving together with Alaunos Stock
Moving against Alaunos Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Alaunos Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Chairman CEO | Holger CPA | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsAlaunos Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Alaunos Therapeutics' financial leverage. It provides some insight into what part of Alaunos Therapeutics' total assets is financed by creditors.
| |||||
Alaunos Therapeutics (TCRT) is traded on NASDAQ Exchange in USA and employs 1 people. Alaunos Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 6.22 M. Alaunos Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 2.21 M outstanding shares of which 108.94 K shares are at this time shorted by private and institutional investors with about 0.1 trading days to cover.
Alaunos Therapeutics currently holds about 60.01 M in cash with (4.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.28.
Check Alaunos Therapeutics Probability Of Bankruptcy
Ownership AllocationAlaunos Therapeutics shows 3.78 percent of its outstanding shares held by insiders and 4.76 percent owned by other corporate entities.
Check Alaunos Ownership Details
Alaunos Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Barclays Plc | 2025-06-30 | 100.0 | |
| Royal Bank Of Canada | 2025-03-31 | 100.0 | |
| Federation Des Caisses Desjardins Du Quebec | 2025-06-30 | 86.0 | |
| Bank Of America Corp | 2025-06-30 | 85.0 | |
| Bank Of Oklahoma National Association | 2025-06-30 | 66.0 | |
| Asset Dedication, Llc | 2025-06-30 | 46.0 | |
| Key Financial, Inc. | 2025-06-30 | 24.0 | |
| Newbridge Financial Services Group, Inc. | 2025-06-30 | 24.0 | |
| Signaturefd, Llc | 2025-06-30 | 23.0 | |
| Blackrock Inc | 2025-06-30 | 21.4 K | |
| Vanguard Group Inc | 2025-06-30 | 21 K |
Alaunos Therapeutics Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Alaunos Therapeutics market risk premium is the additional return an investor will receive from holding Alaunos Therapeutics long position in a well-diversified portfolio.
| Mean Deviation | 5.04 | |||
| Semi Deviation | 5.54 | |||
| Standard Deviation | 6.69 | |||
| Variance | 44.72 |
Alaunos Stock Against Markets
Alaunos Therapeutics Corporate Management
| Abhishek Srivastava | VP Operations | Profile | |
| Michael Wong | Vice Officer | Profile | |
| Melinda Lackey | Administration Legal | Profile | |
| Ferdinand Groenewald | Vice Finance | Profile | |
| Kevin Sr | CEO Director | Profile |
Additional Tools for Alaunos Stock Analysis
When running Alaunos Therapeutics' price analysis, check to measure Alaunos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alaunos Therapeutics is operating at the current time. Most of Alaunos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Alaunos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alaunos Therapeutics' price. Additionally, you may evaluate how the addition of Alaunos Therapeutics to your portfolios can decrease your overall portfolio volatility.